Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 8,256 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 8,256 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $9.37, for a total value of $77,358.72. Following the transaction, the director now owns 772,277 shares of the company’s stock, valued at approximately $7,236,235.49. The trade was a 1.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Olema Pharmaceuticals Trading Up 0.4 %

OLMA opened at $6.75 on Friday. The firm has a market cap of $386.76 million, a P/E ratio of -3.08 and a beta of 1.92. Olema Pharmaceuticals, Inc. has a 12 month low of $6.24 and a 12 month high of $16.77. The stock has a 50-day moving average of $10.70 and a 200 day moving average of $11.86.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in OLMA. Conway Capital Management Inc. purchased a new position in Olema Pharmaceuticals in the third quarter worth about $119,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Olema Pharmaceuticals by 67.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock valued at $132,000 after buying an additional 4,442 shares during the period. Portland Investment Counsel Inc. purchased a new position in shares of Olema Pharmaceuticals during the third quarter valued at approximately $143,000. Cubist Systematic Strategies LLC purchased a new position in shares of Olema Pharmaceuticals during the second quarter valued at approximately $145,000. Finally, SG Americas Securities LLC purchased a new position in shares of Olema Pharmaceuticals during the third quarter valued at approximately $156,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Wednesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $27.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.